©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 6, 2022; 10(28): 10193-10200
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10193
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10193
Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report
Lin-Jie Li, Jun-Yu Zhang, Department of Hematology, Lishui Municipal Central Hospital, Lishui 323000, Zhejiang Province, China
Author contributions: Zhang JY designed the report and wrote the paper; Li LJ collected the patient’s clinical data; all authors have read and approved the final version of this manuscript.
Supported by the Medical Health Science and Technology Project of Zhejiang Province Health Commission , No. 2020376298 .
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Corresponding author: Lin-Jie Li, Doctor, Chief Doctor, Department of Hematology, Lishui Municipal Central Hospital, No. 289 Kuocang Load, Lishui 323000, Zhejiang Province, China. lilinjie0394@163.com
Received: April 9, 2022
Peer-review started: April 9, 2022
First decision: June 16, 2022
Revised: June 24, 2022
Accepted: August 24, 2022
Article in press: August 24, 2022
Published online: October 6, 2022
Processing time: 167 Days and 4.5 Hours
Peer-review started: April 9, 2022
First decision: June 16, 2022
Revised: June 24, 2022
Accepted: August 24, 2022
Article in press: August 24, 2022
Published online: October 6, 2022
Processing time: 167 Days and 4.5 Hours
Core Tip
Core Tip: Extranodal natural killer/T cell lymphoma nasal type is a highly aggressive malignancy characterized by its association with Epstein-Barr virus and extranodal involvement, which shows a poor clinical outcome. Now, we report a rare case of relapsed/refractory classic Hodgkin lymphoma with resistance to anti-PD-1 in which anti-PD-1 combined with decitabine showed positive preliminary results. Our findings support the potential benefit of anti-PD-1 combined with decitabine in this type of refractory T-cell lymphoma.